Presoaked IOLs show dual action

Article

Intraocular lenses (IOLs) soaked in antibiotics have antimicrobial properties, according to results published in the October issue of the Journal of Ocular Pharmacology and Therapeutics.

Intraocular lenses (IOLs) soaked in antibiotics have antimicrobial properties, according to results published in the October issue of the Journal of Ocular Pharmacology and Therapeutics.

Edward F. Smith of the department of ophthalmology at the State University of New York (SUNY), US and colleagues immersed six groups (each group, n=8–10) of commercially available IOLs in fourth-generation fluoroquinolones as follows: 1.8 µg/mL moxifloxacin for 60 minutes; 5 mg/mL moxifloxacin for one minute; 5 mg/mL moxifloxacin for 60 minutes; 0.48 µg/mL gatifloxacin for 60 minutes; 3 mg/mL gatifloxacin for one minute; and 3 mg/mL gatifloxacin for 60 minutes. A control group of IOLs was soaked in saline for 60 minutes. The IOLs were placed in agar with an overlay of S. aureus and after 24 hours, the team measured bacterial kill zones.

Among the groups soaked in lower-strength doses of antibiotic for 60 minutes, the 0.48 µg/mL gatifloxacin and saline produced no measurable bacterial kill zone, whereas the 1.8 µg/mL moxifloxacin group produced a bacterial kill zone of 3.88±3.18 mm. A kill zone of ≥33 mm was achieved by all groups soaked in high dose fluoroquinolones: for the 5 mg/mL moxifloxacin group (one minute), this was 38.80±3.74 mm; 3 mg/mL gatifloxacin (one minute), 34.30±1.34 mm; 5 mg/mL moxifloxacin (60 minutes), 33.56±1.42 mm; 3 mg/mL gatifloxacin (60 minutes), 33.67±0.50 mm.

Thus the researchers concluded that soaking IOLs in high (commercial) levels of fluoroquinolones produces IOLs with antimicrobial properties in vitro. The widest bacterial kill zone was achieved with IOLs immersed for one minute in 5 mg/mL of moxifloxacin.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.